linjc16/ctgov huggingface dataset:
MRD Application in Colorectal Cancer Patients

Study Overview
=================
Brief Summary
-----------------
We first collect tumor tissue and adjacent tissue to peform the WES sequencing, then collect blood after postoperative surgery 1, 3. 6, 9, 12, 18, 24 month to detect ctDNA.

Detailed Description
-----------------
ctDNA is obtained from plasma rather than serum, as the latter contains more DNA released from immune cells during clotting. Blood should be drawn into a K2EDTA or cell stabilization tube (e.g., Streck cfDNA collection tube). Plasma isolation should be performed as soon as possible, no later than 24 hours, using K2EDTA (preferably within 4-6 hours) and, if using cell stabilization tubes, within 2-7 days, temporarily stored at 4°C. Sample disposal procedure: collect whole anticoagulated blood, gently invert to fully anticoagulate, plasma fractionation should be performed as soon as possible, no later than 24 hours, temporarily stored at 4°C using K2EDTA (preferably within 4-6 hours), and stored at -80°C for long term. The collected anticoagulant blood is placed in an ice box containing ice packs and transported vertically to a centrifugable laboratory. Centrifuge at 3000 rpm at 4°C for 15 min, take the upper layer, and aliquot 0.5 mL/tube into 1.5 mL centrifuge tubes. Cryopreserved at -80 °C, 1 mL of whole blood yields approximately 0.5 mL of plasma.

Official Title
-----------------
ctDNA Monitoring Cancer Recurrence and Its Clinical Value in Solid Tumor

Conditions
-----------------
Surgery, Colorectal Cancer, Chemotherapy Effect

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Patients with colorectal tumors, whose clinical symptoms meet the diagnostic criteria of colon cancer in my country, and pathologically diagnosed as colorectal cancer after surgery; (2) patients with stage II-III colorectal cancer; (3) aged 30-80 years; (4) All underwent conventional radiotherapy and chemotherapy after operation; (5) Complete clinical data and follow-up records were available. Exclusion Criteria: (1) Other serious diseases (cardiovascular and cerebrovascular diseases, kidney diseases, etc.) before operation; (2) Combined with multiple primary colorectal cancers; (3) Patients with other malignant tumors within the past 5 years; (4) Combined with digestive tract Obstruction, perforation, bleeding and other indications for emergency surgery.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ctDNA positive patients are detedcted before PET-CT | multiple PCR based on the WES results | 2023.12.31 |
Paternal Age and Fetal Aneuploidy

Study Overview
=================
Brief Summary
-----------------
Trisomy 21, commonly known as down syndrome, is the most common chromosomal abnormality in humans. Advanced maternal age (AMA) is a well-recognized risk factor for trisomy 21, with the risk increasing significantly beyond the age of 35. Research on the effects of paternal age on the prenatal risk of trisomy 21 is lacking, with inconsistent findings in the literature. The Harmony® prenatal test is an Non-Invasive Prenatal Testing (NIPT) that screens maternal blood for chromosomal abnormalities in the Cell-Free Fetal DNA (cfDNA). The harmony® prenatal test can detect conditions such as trisomy 13, 18, and 21, as well as sex chromosome abnormalities. The Optimo test is a prenatal screening test that screens for trisomies 13, 18 and 21 in the developing fetus using extended biochemical screening in maternal. The Optimo test has shown high sensitivity and specificity in detecting trisomy 21.

Official Title
-----------------
Exploring the Association Between Paternal Age and Trisomy 21 Screening Results.

Conditions
-----------------
Trisomy 21

Intervention / Treatment
-----------------
* Diagnostic Test: Optimo prenatal screening test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women aged 18 years or older (at the time of trisomy 18 and 21 screening) and who were able to complete the questionnaire in either French or English Pregnant women who completed the entire trisomy 21 screening process at clinique ovo were included Exclusion Criteria: Patients who did not indicate the male partner/donor's age were excluded Patients who did not complete or sign the clinical information form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trisomy 21 screening results | On the day of the Optimo screening test, a questionnaire concerning clinical data (maternal and paternal age, ethnicity, weight, smoking status, pregnancy history) is completed. Blood test and nuchal transparency are done on that day. Results from serum analysis and nuchal transparency are combined to assess the risk of trisomy 21. Association between paternal age and trisomy 21 screening results will be assessed afterwards | 3 to 5 days |
Reminder-cue Scanning Training for Homonymous Visual Field Loss

Study Overview
=================
Brief Summary
-----------------
This study will evaluate a new approach to training people with visual field loss to scan when driving

Detailed Description
-----------------
Homonymous visual field loss is the loss of vision on the same side in both eyes. The most common types are hemianopia (the loss of one half of the field of vision) and quadrantanopia (the loss of one quarter of the field of vision). Hemianopia and quadrantanopia may cause difficulties in seeing objects on the side of the field loss. People with these types of field loss can compensate by scanning (looking) toward the side of the field loss. However, sometimes they might not scan sufficiently well resulting in delayed responses to hazards when driving. The purpose of this research study is to evaluate a new approach, reminder-cue scanning training, to training people with homonymous visual field loss to scan when driving. Participants will receive reminder-cue scanning training in the driving simulator.Typically there will be three training sessions within about a 2-week period. In addition, participants will complete an evaluation in the driving simulator before and after the training.

Official Title
-----------------
Reminder-cue Scanning Training for People With Homonymous Visual Field Loss

Conditions
-----------------
Homonymous Hemianopia, Homonymous Quadrantanopia

Intervention / Treatment
-----------------
* Behavioral: Reminder-cue scanning training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Homonymous hemianopia or homonymous quadrantanopia for at least 3 months Binocular visual acuity of at least 20/40 Prior or current driving experience Able to attend multiple study visits Able to communicate in English sufficiently to understand the study procedures Exclusion Criteria: Hemi-spatial neglect Significant cognitive impairment Physical or general health problems that could impair the ability to operate the controls of the driving simulator or participate in the training

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: StudyArm<br>Participants will receive reminder-cue scanning training in a driving simulator. | Behavioral: Reminder-cue scanning training<br>* Auditory reminders to scan when scanning to the side of the field loss is inadequate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in rate of adequate scanning to the side of the field loss | Proportion of intersections at which scanning was adequate to the side of the field loss | Pre-training, post-training (up to 6 weeks) |
Development of a Canadian Bronchiectasis and NTM Database

Study Overview
=================
Brief Summary
-----------------
The investigators aim to develop a comprehensive patient registry of patients with non-CF bronchiectasis and/or Nontuberculosis Mycobacteria (NTM)

Detailed Description
-----------------
The investigators aim to develop a comprehensive patient registry of patients with non-CF bronchiectasis and/or Nontuberculosis Mycobacteria (NTM). This will entail inclusion of adults (age >18 years) with a diagnosis of these conditions to be entered with complete clinical data and quality of life assessments entered into a patient registry.

Official Title
-----------------
Development of a Canadian Bronchiectasis and NTM Database

Conditions
-----------------
Bronchiectasis, Non-Tuberculous Mycobacterial Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over the age of 18 Non-CF Bronchiectasis Nontuberculosis Mycobacteria (NTM) Exclusion Criteria: Under the age of 18 CF bronchiectasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-CF Bronchiectasis Patients with or without NTM<br>Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM). | |
| Nontuberculosis Mycobacteria (NTM)<br>Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Recruitment and Data analysis for NTM and Bronchiectasis | Descriptive analysis of demographics and clinical parameters and epidemiological evaluation of No. of hospitalizations, No. of exacerbations. | December 2050 |
Kalifilcon A Toric Compared to Commercially Available Lenses

Study Overview
=================
Brief Summary
-----------------
Approximately 30 soft toric contact lens adapted subjects will be enrolled in this feasibility, bilateral, randomized, double masked (subject and investigator masked), repeated measures insertion study. All subjects will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If subjects satisfy all eligibility criteria and none of the exclusion criteria, subjects will have study lenses inserted in random, successive order according to unique randomization schedules that will be provided to each Investigator.

Official Title
-----------------
Orientation Characteristics of Kalifilcon A Daily Disposable Toric Contact Lenses Compared to Commercially Available Daily Disposable Toric Contact Lenses

Conditions
-----------------
Refractive Ametropia

Intervention / Treatment
-----------------
* Device: Kalifilcon Toric Lens
* Device: Total1 for Astigmatism
* Device: Precision1 for Astigmatism
* Device: MyDay Toric


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have capacity to read, understand and provide written voluntary informed consent. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. Have no active ocular disease or allergic conjunctivitis. Not be using any topical ocular medications. Be willing and able to follow instructions. Have signed a statement of informed consent. Exclusion Criteria: Participating in a conflicting study in the opinion of the Investigator. Considered by the Investigator to not be a suitable candidate for participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Kalifilcon A Daily Disposable Toric<br>Kalifilcon A Daily Disposable Toric | Device: Kalifilcon Toric Lens<br>* Kalifilcon A Daily Disposable Toric for Ametropia<br>|
| Active Comparator: Total1 for Astigmatism<br>Total1 for Astigmatism | Device: Total1 for Astigmatism<br>* Total1 for Astigmatism<br>|
| Active Comparator: Precision1 for Astigmatism<br>Precision1 for Astigmatism | Device: Precision1 for Astigmatism<br>* Precision1 for Astigmatism<br>|
| Active Comparator: MyDay Toric<br>MyDay Toric | Device: MyDay Toric<br>* MyDay Toric<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary gaze orientation for 5 minutes | Primary gaze orientation is measured in degrees using a slit lamp and reticule. | 5 minutes after lens insertion |
Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality from the disease. However, current urinary biomarkers have insufficient specificity to warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from patients with BCa and controls to compare the glycosaminoglycan profiles between groups.

Official Title
-----------------
Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Free glycosaminoglycan profiling


Participation Criteria
=================
Eligibility Criteria
-----------------
Cases (Bladder cancer [BCa]) Inclusion Criteria: Primary BCa diagnosis at cystoscopy, planned for TURB Exclusion Criteria: No histopathological diagnosis of BCaTa-T4 N0-2 MX-0 after TURB Controls (No evidence of disease [NED]) Inclusion Criteria: In follow-up with cystoscopy after treatment Ta-T3 N0-2 M0 BCa or upper tract urothelial cancer no evidence of disease at cystoscopy for at least 6 months prior to inclusion No history of cancer except urothelial Exclusion Criteria: Positive cytology at inclusion visit Intravesical instillation therapy during 6 months prior to inclusion visit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bladder cancer<br> | Diagnostic Test: Free glycosaminoglycan profiling<br>* Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.<br>|
| No evidence of disease<br> | Diagnostic Test: Free glycosaminoglycan profiling<br>* Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area-under-the-receiving operating characteristic (ROC)-curve (AUC) for the classification of BCa versus NED |  | Before primary surgery for BCa; at a post-surgical follow-up visit for controls up to 5 years from primary surgery |
The Negative Pressure Wound Therapy in Flap Salvage

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to compare the clinical outcomes of using NPWT dressing versus conventional dressing over fasciocutaneous flaps.

Detailed Description
-----------------
The cases will be divided into 2 major study groups: 1st group will be managed with NPWT and will be divided into 2 subgroups: low pressure therapy and high pressure therapy groups The 2nd group will be managed with conventional dressing

Official Title
-----------------
Negative Pressure Wound Therapy in Flap Salvage

Conditions
-----------------
Surgical Flap, Negative-Pressure Dressings

Intervention / Treatment
-----------------
* Device: NPWT
* Other: Conventional dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Adult patients post-traumatic or post-tumor excision soft tissue defects fascio-cutaneous flaps Exclusion Criteria: associated severe regional injuries uncontrolled comorbidities established flap compromise revision cases

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Negative pressure wound therapy (vacuum-assisted wound closure) for postoperative flap care
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: High negative pressure group<br>A high negative pressure amplitude is applied over the flaps | Device: NPWT<br>* the NPWT dressing applied to fasciocutaneous flap<br>* Other names: VAC;|
| Active Comparator: Low negative pressure group<br>A low negative pressure amplitude is applied over the flaps | Device: NPWT<br>* the NPWT dressing applied to fasciocutaneous flap<br>* Other names: VAC;|
| Placebo Comparator: Control group<br>Conventional dressing is applied over the flaps | Other: Conventional dressing<br>* Conventional dressing ( topical care ) applied to fasciocutaneous flap<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with primary healing | Healing by epithelization without the need for secondary intervention | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with flap Edema | flap edema clinical & radiological assessment | 1 week | 
| Number of Participants with flap Congestion | flap congestion clinical assessment | 1 week | 
| Number of Participants with flap Ischemia | flap ischemia clinical assessment | 1 week | 
| Number of Participants with flap infection | surgical site infection | 2 weeks |
Surgically Treated Displaced Mid-diaphyseal Clavicle Fractures

Study Overview
=================
Brief Summary
-----------------
This prospective, multi-centre study aims to determine clinical, radiographic, and patient-reported outcomes (PROMs) following surgical fixation of displaced mid-diaphyseal clavicle fractures and to compare implant removal rates between techniques within 2-years of the procedure.

Detailed Description
-----------------
Given the substantially lower implant removal rate in combination with a high union rate with the dual mini-fragment technique, we do not believe there is clinical equipoise required for a randomized clinical trial. This study is a multi-centre, prospective cohort study (11 sites confirmed to date) of all operatively treated clavicle fractures, in order to objectively evaluate all current surgical techniques used across Canada. This pragmatic approach will allow us to observe surgical decision-making, rationale for implant removal, and report on clinical, radiographic, and patient-reported outcomes for all techniques over a 2-year follow-up timeframe, for the first time. All enrolled patients will be encouraged to begin immediate range of motion as tolerated and weightbearing as tolerated post-operatively. This will be assessed at each follow-up and any reason for delayed motion or weightbearing will be reported.

Official Title
-----------------
A Multi-Centre Prospective Cohort Study of Surgically Treated Displaced Mid-diaphyseal Clavicle Fractures

Conditions
-----------------
Clavicle Fracture

Intervention / Treatment
-----------------
* Procedure: surgical fixation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treated with surgical fixation for a displace mid-diaphyseal clavicle fracture. Aged 18 years of age or older and skeletally mature. Enrolled within 21 (+3 days) of injury. Willing and able to complete consent and study participation. Exclusion Criteria: Pathological fractures. Clavicle non-unions. Current or prior ipsilateral upper extremity injury that may impact functional outcomes. Polytrauma patients with injuries projected to affect rehabilitation course. Active malignancy. Inability to provide consent or complete follow-up. Incarcerated patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: surgical fixation|compare implant removal rates between surgical fixation techniques.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine implant removal rates | To report implant removal rates in an appropriately powered prospective cohort study. | 4 years | 
| Identify rationale for implant removal | To report rationale for implant removal in an appropriately powered prospective cohort study. | 4 years |